|
humans |
30 |
|
male |
28 |
|
female |
27 |
|
middle aged |
23 |
|
aged |
21 |
|
parkinson's disease |
21 |
|
medical sciences |
19 |
|
adult |
18 |
|
stroke |
17 |
|
hypertension |
13 |
|
als |
12 |
|
adolescent |
11 |
|
blood pressure |
11 |
|
case-control studies |
11 |
|
dti |
11 |
|
intracerebral hemorrhage |
10 |
|
mutation |
10 |
|
statistics, nonparametric |
10 |
|
endothelial function |
9 |
|
family health |
9 |
|
garlic |
9 |
|
ischemic stroke |
9 |
|
analysis of variance |
8 |
|
animals |
8 |
|
blood pressure variability |
8 |
|
cardiomyopathy |
8 |
|
cardiovascular and cerebrovascular diseases |
8 |
|
chi-square distribution |
8 |
|
denture, complete |
8 |
|
electromyography |
8 |
|
genetics |
8 |
|
induced pluripotent stem cells |
8 |
|
magnetic resonance imaging |
8 |
|
magnetic resonance imaging - methods |
8 |
|
mortality |
8 |
|
neuropathy |
8 |
|
oxidative stress |
8 |
|
superoxide dismutase - genetics |
8 |
|
type 2 diabetes mellitus |
8 |
|
vascular markers |
8 |
|
vascular markers of atherosclerosis |
8 |
|
young adult |
8 |
|
5' untranslated regions - genetics |
7 |
|
antiplatelet medication |
7 |
|
asian continental ancestry group - ethnology |
7 |
|
charcot-marie-tooth |
7 |
|
charcot-marie-tooth disease - genetics - pathology - physiopathology |
7 |
|
child |
7 |
|
connexins - genetics |
7 |
|
cutoff |
7 |
|
dna mutational analysis |
7 |
|
genetic diseases, x-linked - genetics |
7 |
|
gjb1 (connexin32) |
7 |
|
hematoma location |
7 |
|
lacunar infarct |
7 |
|
microscopy, electron, transmission |
7 |
|
neural conduction - genetics - physiology |
7 |
|
neuroprotection |
7 |
|
next generation sequencing |
7 |
|
non-coding region |
7 |
|
peripheral nerves - pathology - physiopathology - ultrastructure |
7 |
|
point mutation - genetics |
7 |
|
psychiatry and neurology |
7 |
|
reproducibility of results |
7 |
|
sequence analysis |
7 |
|
stroke outcome |
7 |
|
survival |
7 |
|
alff |
6 |
|
amyotrophic lateral sclerosis - enzymology - genetics - pathology |
6 |
|
amyotrophic lateral sclerosis - genetics |
6 |
|
anisotropy |
6 |
|
asian continental ancestry group |
6 |
|
ciliary neurotrophic factor - genetics |
6 |
|
cntf |
6 |
|
coronary artery disease |
6 |
|
deferiprone |
6 |
|
diffusion magnetic resonance imaging - methods |
6 |
|
diffusivity |
6 |
|
dna mutational analysis - methods |
6 |
|
exons - genetics |
6 |
|
familial |
6 |
|
familial amyotrophic lateral sclerosis |
6 |
|
friedreich ataxia |
6 |
|
friedreich's ataxia |
6 |
|
functional connectivity |
6 |
|
functional mri |
6 |
|
ich volume |
6 |
|
idebenone |
6 |
|
image processing, computer-assisted |
6 |
|
intraventricular extension |
6 |
|
isoleucine - genetics |
6 |
|
mediterranean-style diet |
6 |
|
multimodal |
6 |
|
mutations |
6 |
|
neurological deterioration |
6 |
|
nonsymptomatic |
6 |
|
pedigree |
6 |
|
phenotype |
6 |
|
resting state |
6 |
|
reverse transcriptase polymerase chain reaction - methods |
6 |
|
sensitivity and specificity |
6 |
|
sod1 |
6 |
|
sod1 mutation |
6 |
|
threonine - genetics |
6 |
|
vascular endothelial growth factor a - genetics |
6 |
|
vegf |
6 |
|
visual hallucinations |
6 |
|
visual spatial memory |
6 |
|
warfarin |
6 |
|
warfarin-associated ich |
6 |
|
amygdala |
5 |
|
animals, newborn |
5 |
|
autoantibodies - blood |
5 |
|
cerebral ischemia |
5 |
|
chlorides - diagnostic use |
5 |
|
classical multiple sclerosis |
5 |
|
contrast media |
5 |
|
dementia |
5 |
|
denture, partial |
5 |
|
edentulous |
5 |
|
equipment design |
5 |
|
exome sequencing |
5 |
|
fatal outcome |
5 |
|
follow-up |
5 |
|
free radicals |
5 |
|
glutamate excitotoxicity |
5 |
|
glutamate-ammonia ligase - metabolism |
5 |
|
glutamine synthetase |
5 |
|
hippocampus |
5 |
|
hong kong |
5 |
|
hypoxia |
5 |
|
hypoxia-ischemia, brain - enzymology - metabolism - pathology |
5 |
|
image processing, computer-assisted - methods |
5 |
|
intracranial hemorrhage |
5 |
|
iron deposition |
5 |
|
jaw, edentulous, partially - physiopathology |
5 |
|
manganese compounds - diagnostic use |
5 |
|
manganese-enhanced mri |
5 |
|
mendelian disease |
5 |
|
mitochondria |
5 |
|
mitochondrial dysfunction |
5 |
|
mn-superoxide dismutase |
5 |
|
motor skills |
5 |
|
motor system |
5 |
|
mouth - physiopathology |
5 |
|
mouth, edentulous - complications - physiopathology |
5 |
|
mouth, edentulous - physiopathology |
5 |
|
myocardial infarction |
5 |
|
neonatal rat |
5 |
|
neurodegeneration |
5 |
|
neurologic examination |
5 |
|
neuromyelitis optica |
5 |
|
oral perception |
5 |
|
parkinson disease |
5 |
|
parkinson disease - physiopathology |
5 |
|
parkinsonian disorders - complications - physiopathology |
5 |
|
psychomotor disorders - physiopathology |
5 |
|
quality control |
5 |
|
quantitative susceptibility mapping |
5 |
|
rats |
5 |
|
rats, sprague-dawley |
5 |
|
recurrence |
5 |
|
secondary prevention |
5 |
|
statistics as topic |
5 |
|
stereognosis |
5 |
|
stereognosis - physiology |
5 |
|
stroke - complications - physiopathology - rehabilitation |
5 |
|
stroke - physiopathology |
5 |
|
superoxide dismutase - metabolism |
5 |
|
surface properties |
5 |
|
survivors |
5 |
|
ucp4 |
5 |
|
uncoupling protein |
5 |
|
uncoupling proteins |
5 |
|
variant annotation |
5 |
|
variant prioritization |
5 |
|
1-methyl-4-phenylpyridinium - metabolism |
4 |
|
1-methyl-4-phenylpyridinium - toxicity |
4 |
|
activities of daily living |
4 |
|
adenosine triphosphate - genetics - metabolism |
4 |
|
adenosine triphosphate - metabolism |
4 |
|
age factors |
4 |
|
aged, 80 and over |
4 |
|
algorithms |
4 |
|
amyotrophic lateral sclerosis |
4 |
|
antibodies - immunology |
4 |
|
antiparkinson agents - therapeutic use |
4 |
|
apoptosis |
4 |
|
aquaporin 4 - biosynthesis - genetics |
4 |
|
aquaporin 4 - immunology |
4 |
|
aquaporin-4 autoantibodies |
4 |
|
aquaporin-4 water channel |
4 |
|
atp |
4 |
|
atp2b4 |
4 |
|
autoimmune diseases of the nervous system - immunology |
4 |
|
autophagosome |
4 |
|
benign paroxysmal positional vertigo |
4 |
|
calcium transient |
4 |
|
cancer |
4 |
|
cell fractionation |
4 |
|
cell line |
4 |
|
cell line, tumor |
4 |
|
cell survival |
4 |
|
cervical vertebrae |
4 |
|
cloning, molecular |
4 |
|
compute tomography |
4 |
|
cross-sectional studies |
4 |
|
cytoprotection |
4 |
|
databases, genetic |
4 |
|
demyelinating diseases - immunology |
4 |
|
dermatomyositis - etiology - therapy |
4 |
|
diagnosis, differential |
4 |
|
dopamine |
4 |
|
dopamine - metabolism |
4 |
|
dopamine - pharmacology |
4 |
|
epidemiologic studies |
4 |
|
epidemiology |
4 |
|
expand disability status scale |
4 |
|
expanded disability status scale score |
4 |
|
familial spastic paraplegia |
4 |
|
fever of unknown origin - microbiology - radiography |
4 |
|
fluorescent antibody technique, indirect |
4 |
|
flux |
4 |
|
gene expression profiling - instrumentation - methods |
4 |
|
glycolysis - drug effects |
4 |
|
herbicides - toxicity |
4 |
|
hong kong - epidemiology |
4 |
|
hong kong chinese |
4 |
|
idiopathic inflammatory demyelinating disorders |
4 |
|
idiopathic relapsing transverse myelitis |
4 |
|
immunization |
4 |
|
immunodominant epitopes - chemistry - immunology |
4 |
|
immunoglobulin g - blood |
4 |
|
incidence |
4 |
|
information storage and retrieval - methods |
4 |
|
ion channels - genetics - metabolism |
4 |
|
ion channels - genetics - physiology |
4 |
|
lc3 |
4 |
|
leptin - pharmacology |
4 |
|
logistic models |
4 |
|
longitudinally extensive transverse myelitis |
4 |
|
lymphatic metastasis |
4 |
|
lysosome |
4 |
|
membrane potential, mitochondrial |
4 |
|
membrane potential, mitochondrial - drug effects |
4 |
|
membrane transport proteins - genetics - immunology - metabolism |
4 |
|
membrane transport proteins - genetics - metabolism |
4 |
|
minimally conscious state |
4 |
|
mitochondria - drug effects - metabolism |
4 |
|
mitochondria - genetics - immunology - metabolism |
4 |
|
mitochondrial membrane potential |
4 |
|
mitochondrial proteins - genetics - metabolism |
4 |
|
mitochondrial proteins - genetics - physiology |
4 |
|
motor neuron disease |
4 |
|
motor neuron disease - diagnosis - epidemiology |
4 |
|
motor neuron disease - etiology - therapy |
4 |
|
mpp + |
4 |
|
mpp+ |
4 |
|
multiple sclerosis - immunology |
4 |
|
myasthenia gravis |
4 |
|
myasthenia gravis - immunology - metabolism - pathology |
4 |
|
myelitis, transverse - immunology |
4 |
|
myositis - etiology - therapy |
4 |
|
nasopharyngeal carcinoma |
4 |
|
nasopharyngeal neoplasms - complications |
4 |
|
neoplasm recurrence, local - complications - therapy |
4 |
|
nerve tissue proteins - genetics - metabolism |
4 |
|
neuromyelitis optica - immunology |
4 |
|
neuromyelitis optica-igg |
4 |
|
neurons - drug effects - metabolism - pathology |
4 |
|
neurons - immunology - metabolism - pathology |
4 |
|
neuroprotective agents - pharmacology |
4 |
|
oligonucleotide array sequence analysis - instrumentation - methods |
4 |
|
optic neuritis - immunology |
4 |
|
oxidative phosphorylation |
4 |
|
oxidative stress - drug effects |
4 |
|
paraneoplastic inflammatory myopathy |
4 |
|
paraneoplastic motor neuropathy |
4 |
|
paraneoplastic neurological disorders |
4 |
|
paraneoplastic syndromes - etiology - therapy |
4 |
|
parkinsonism |
4 |
|
peptides - administration & dosage - chemical synthesis |
4 |
|
pmca |
4 |
|
pregnancy |
4 |
|
pregnancy complications, infectious - etiology - radiography |
4 |
|
prevalence |
4 |
|
relapsing remitting multiple sclerosis |
4 |
|
retrospective studies |
4 |
|
rna, small interfering |
4 |
|
secondary progression multiple sclerosis |
4 |
|
sex factors |
4 |
|
sheep |
4 |
|
standard deviation |
4 |
|
superoxides - metabolism |
4 |
|
thymoma |
4 |
|
thymoma - immunology - metabolism - pathology |
4 |
|
thymus neoplasms - immunology - metabolism - pathology |
4 |
|
tomography, x-ray computed - methods |
4 |
|
transgenes - genetics |
4 |
|
treatment outcome |
4 |
|
tuberculoma - complications - radiography |
4 |
|
tuberculosis, meningeal - complications - radiography |
4 |
|
ucp |
4 |
|
β-interferon |
4 |
|
1-methyl-4-phenylpyridinium |
3 |
|
acetylcholine receptor autoantibodies |
3 |
|
actins - toxicity |
3 |
|
acute disease |
3 |
|
acute transverse myelitis |
3 |
|
adenosine triphosphate - deficiency |
3 |
|
affective symptoms - etiology |
3 |
|
age of onset |
3 |
|
aging |
3 |
|
angiography, digital subtraction |
3 |
|
anti-coagulation |
3 |
|
anti-inflammatory agents - therapeutic use |
3 |
|
anticoagulants - therapeutic use |
3 |
|
antihypertensive agents - adverse effects - pharmacology - therapeutic use |
3 |
|
antineoplastic combined chemotherapy protocols - administration & dosage - therapeutic use |
3 |
|
antioxidants - metabolism |
3 |
|
antiviral agents - therapeutic use |
3 |
|
apoptosis - physiology |
3 |
|
asian continental ancestry group - statistics & numerical data |
3 |
|
bath-related headache |
3 |
|
baths - adverse effects |
3 |
|
biological evolution |
3 |
|
biopsy |
3 |
|
blotting, western |
3 |
|
brain - blood supply |
3 |
|
brain - pathology |
3 |
|
brain - pathology - virology |
3 |
|
brain - physiology |
3 |
|
brain diseases - diagnosis |
3 |
|
brain edema - etiology |
3 |
|
brain ischemia - etiology - physiopathology |
3 |
|
brain neoplasms - complications - pathology - secondary |
3 |
|
brainstem |
3 |
|
bromocriptine - therapeutic use |
3 |
|
c-rel |
3 |
|
carcinogenesis |
3 |
|
carcinoma, non-small-cell lung - complications - pathology - secondary |
3 |
|
carotid arteries - pathology |
3 |
|
carotid artery diseases |
3 |
|
carrier proteins - physiology |
3 |
|
caspase 3 - metabolism |
3 |
|
catechol o-methyltransferase - biosynthesis |
3 |
|
catecholamines - physiology |
3 |
|
catechols - metabolism - pharmacology - toxicity |
3 |
|
cell survival - physiology |
3 |
|
cerebral arteries |
3 |
|
cerebral arteries - metabolism |
3 |
|
cerebral haemorrhage |
3 |
|
cerebral infarction |
3 |
|
cerebral infarction - etiology - radiography |
3 |
|
cerebral venous thrombosis |
3 |
|
cerebrovascular circulation |
3 |
|
chelating agents - therapeutic use |
3 |
|
child, preschool |
3 |
|
china - ethnology |
3 |
|
chinese |
3 |
|
cognition - physiology |
3 |
|
comt |
3 |
|
comt assay |
3 |
|
confusion - etiology |
3 |
|
coronary artery disease vertebral artery |
3 |
|
coronary disease - pathology |
3 |
|
corticosteroid |
3 |
|
cyclosporine - therapeutic use |
3 |
|
demyelinating diseases - diagnosis - etiology - therapy |
3 |
|
demyelinating disorders |
3 |
|
depression |
3 |
|
depressive disorder - complications - pathology - psychology |
3 |
|
dexamethasone - administration & dosage |
3 |
|
dexamethasone - therapeutic use |
3 |
|
diabetes complications - etiology |
3 |
|
diffusion magnetic resonance imaging |
3 |
|
digital subtraction angiography |
3 |
|
disease progression |
3 |
|
dose-response relationship, drug |
3 |
|
down-regulation - physiology |
3 |
|
earache - etiology |
3 |
|
early-onset myasthneia gravis |
3 |
|
ecological risk assessment |
3 |
|
electron transport |
3 |
|
electrophoresis, polyacrylamide gel |
3 |
|
encephalitis |
3 |
|
encephalitis, herpes simplex - pathology |
3 |
|
endocrine disrupting chemicals |
3 |
|
endocrine disruption |
3 |
|
endocrine disruptors - pharmacology |
3 |
|
energy homeostasis |
3 |
|
environment |
3 |
|
environmental pollutants - metabolism - pharmacology - toxicity |
3 |
|
environmental pollutants - toxicity |
3 |
|
epilepsy, generalized - etiology |
3 |
|
estradiol - analogs & derivatives - pharmacology |
3 |
|
estradiol - pharmacology |
3 |
|
estrogen |
3 |
|
estrogen antagonists - pharmacology |
3 |
|
estrogens, non-steroidal |
3 |
|
european continental ancestry group - genetics |
3 |
|
evoked potentials, motor - physiology |
3 |
|
fever - etiology |
3 |
|
follow-up studies |
3 |
|
frontal lobe - pathology |
3 |
|
gene expression regulation - drug effects |
3 |
|
gene expression regulation, developmental - genetics |
3 |
|
gene expression regulation, enzymologic - drug effects |
3 |
|
glaucoma - diagnosis |
3 |
|
guillain-barre syndrome |
3 |
|
guillain-barré syndrome |
3 |
|
headache |
3 |
|
headache - diagnosis - etiology - therapy |
3 |
|
headache - etiology |
3 |
|
heparin, low-molecular-weight - therapeutic use |
3 |
|
hepatitis e |
3 |
|
hepatitis e virus |
3 |
|
hepatolenticular degeneration - complications - pathology - psychology |
3 |
|
hereditary sensory and autonomic neuropathies - blood - diagnosis |
3 |
|
hereditary sensory and motor neuropathy - blood - diagnosis |
3 |
|
hypertension - complications - drug therapy |
3 |
|
idiopathic inflammatory |
3 |
|
idiopathic transverse myelitis |
3 |
|
immunosuppressive agents - therapeutic use |
3 |
|
indicators and reagents |
3 |
|
infarction, posterior cerebral artery - etiology - physiopathology |
3 |
|
intelligence - genetics |
3 |
|
intracranial arteriosclerosis - genetics |
3 |
|
intracranial hemorrhages - etiology - pathology - physiopathology |
3 |
|
intracranial thrombosis - complications |
3 |
|
intracranial thrombosis - complications - pathology - physiopathology |
3 |
|
ion channels |
3 |
|
l-lactate dehydrogenase - metabolism |
3 |
|
language |
3 |
|
large artery infarct |
3 |
|
late-onset myasthenia gravis |
3 |
|
leukemia, lymphoid - complications - drug therapy |
3 |
|
life style |
3 |
|
lung neoplasms - complications - pathology |
3 |
|
lupus erythematosus, systemic - blood - complications |
3 |
|
marine protected areas |
3 |
|
membrane potentials - physiology |
3 |
|
membrane proteins - physiology |
3 |
|
membrane transport proteins - drug effects - genetics - metabolism |
3 |
|
membrane transport proteins - genetics - physiology |
3 |
|
membrane transport proteins - physiology |
3 |
|
mitochondrial membranes - physiology |
3 |
|
mitochondrial proteins - drug effects - genetics - metabolism |
3 |
|
mitochondrial proteins - physiology |
3 |
|
mitoxantrone - administration & dosage |
3 |
|
models, biological |
3 |
|
motor endplate - metabolism |
3 |
|
multiple sclerosis |
3 |
|
muscle, skeletal - metabolism |
3 |
|
myasthenia gravis - diagnosis - epidemiology - therapy |
3 |
|
myelin sheath - pathology |
3 |
|
myelitis, transverse - complications - diagnosis - physiopathology - therapy |
3 |
|
myelitis, transverse - diagnosis - etiology - therapy |
3 |
|
myopia - genetics |
3 |
|
neoplasms - chemically induced - epidemiology |
3 |
|
nephrotic syndrome - complications |
3 |
|
nerve degeneration - etiology |
3 |
|
nerve tissue proteins - drug effects - genetics - metabolism |
3 |
|
nerve tissue proteins - genetics - physiology |
3 |
|
nervous system |
3 |
|
neurodegenerative diseases |
3 |
|
neurons - drug effects - metabolism |
3 |
|
neurons - metabolism |
3 |
|
neurotoxins - toxicity |
3 |
|
nonthymoma-generalized myasthenia gravis |
3 |
|
nuclear factor κb |
3 |
|
nuclear factor-κb |
3 |
|
oriental female |
3 |
|
oxidation-reduction |
3 |
|
oxidative stress - physiology |
3 |
|
paraneoplastic polyneuropathy - etiology |
3 |
|
paresthesia - etiology |
3 |
|
parkinson disease - psychology |
3 |
|
parkinsonian disorders - complications - pathology - psychology |
3 |
|
parkinsons disease |
3 |
|
pcb |
3 |
|
pdq-39 |
3 |
|
penicillamine |
3 |
|
penicillamine - therapeutic use |
3 |
|
phenols - metabolism - pharmacology - toxicity |
3 |
|
phthalate |
3 |
|
phthalic acids - toxicity |
3 |
|
plasmapheresis |
3 |
|
plasticiser |
3 |
|
plasticizers - toxicity |
3 |
|
pleiotropy |
3 |
|
polychlorinated biphenyls - metabolism - pharmacology - toxicity |
3 |
|
polychlorinated biphenyls - pharmacology |
3 |
|
porcine liver |
3 |
|
prognosis |
3 |
|
promoter |
3 |
|
prospective studies |
3 |
|
psychiatry and neurology medical sciences |
3 |
|
pulmonary edema - etiology |
3 |
|
quality of life |
3 |
|
questionnaires |
3 |
|
receptors, estrogen - drug effects |
3 |
|
receptors, nicotinic - immunology |
3 |
|
reliability |
3 |
|
reverse transcriptase polymerase chain reaction |
3 |
|
risk |
3 |
|
risk factors |
3 |
|
rna, messenger - analysis |
3 |
|
rna, small interfering - genetics |
3 |
|
seizures - etiology |
3 |
|
selection, genetic |
3 |
|
sensory-motor system |
3 |
|
severity of illness index |
3 |
|
spinal cord |
3 |
|
striated muscle autoantibodies |
3 |
|
substance abuse, intravenous - complications |
3 |
|
suicide, attempted |
3 |
|
sural nerve - pathology |
3 |
|
surgery |
3 |
|
systemic lupus erythematosus (sle) |
3 |
|
t-lymphocytes - pathology |
3 |
|
temporal lobe - pathology |
3 |
|
thermogenesis - physiology |
3 |
|
thunderclap headache |
3 |
|
thyroid hormones - physiology |
3 |
|
tomography, x-ray computed |
3 |
|
transcription regulation |
3 |
|
transfection |
3 |
|
trientine - therapeutic use |
3 |
|
trientine hydrochloride |
3 |
|
triggering agents |
3 |
|
trihexyphenidyl - therapeutic use |
3 |
|
tuberculoma, intracranial - diagnosis |
3 |
|
tuberculosis, meningeal - complications - drug therapy - radiography |
3 |
|
tuberculous meningitis |
3 |
|
uncoupling agents |
3 |
|
uncoupling protein 4 |
3 |
|
urinary retention - etiology |
3 |
|
validity |
3 |
|
vasoconstriction |
3 |
|
venous thrombosis - complications |
3 |
|
venous thrombosis - complications - pathology - physiopathology |
3 |
|
vertebral artery - pathology |
3 |
|
vidarabine - administration & dosage - analogs & derivatives |
3 |
|
viral encephalitis |
3 |
|
vision disorders - etiology |
3 |
|
visuomotor control |
3 |
|
warfarin - therapeutic use |
3 |
|
wernicke encephalopathy - complications - diagnosis |
3 |
|
wilson's disease |
3 |
|
xenobiotic catechols |
3 |
|
yeast estrogen screen |
3 |
|
abducens nerve diseases - etiology |
2 |
|
alpha-synuclein |
2 |
|
ambulatory care - economics |
2 |
|
angiography |
2 |
|
angioplasty |
2 |
|
angioplasty, balloon |
2 |
|
antibodies, monoclonal - administration & dosage - therapeutic use |
2 |
|
anticonvulsants - therapeutic use |
2 |
|
antiplatelet |
2 |
|
antitubercular agents - therapeutic use |
2 |
|
atherosclerosis |
2 |
|
attention - drug effects |
2 |
|
basal ganglia |
2 |
|
blood glucose |
2 |
|
blood glucose - analysis |
2 |
|
brain ischemia - complications - pathology |
2 |
|
brain ischemia - prevention & control |
2 |
|
brain neoplasms - diagnosis - physiopathology |
2 |
|
brain stem neoplasms - diagnosis - secondary |
2 |
|
cancer cell |
2 |
|
carcinoma, adenosquamous - complications - diagnosis |
2 |
|
carcinoma, hepatocellular - diagnosis - pathology |
2 |
|
carotid artery disease |
2 |
|
carotid artery stenosis |
2 |
|
carotid artery, common - surgery |
2 |
|
carotid artery, internal - physiopathology - surgery |
2 |
|
carotid stenosis - diagnosis - physiopathology - surgery |
2 |
|
cell growth |
2 |
|
cerebral angiography |
2 |
|
cerebral arteries - pathology |
2 |
|
cerebral cortex |
2 |
|
cerebral hyperperfusion injury |
2 |
|
cerebral infarction - pathology |
2 |
|
cerebral tuberculoma |
2 |
|
cerebral veins |
2 |
|
cerebrospinal fluid |
2 |
|
cerebrospinal fluid - chemistry |
2 |
|
chaperone-mediated autophagy |
2 |
|
china |
2 |
|
china - epidemiology |
2 |
|
cidp |
2 |
|
cluster analysis |
2 |
|
cognition disorders - complications - drug therapy |
2 |
|
corpus striatum - physiopathology |
2 |
|
cost of epilepsy |
2 |
|
cost-of-illness |
2 |
|
diagnostic approach |
2 |
|
diazepam - therapeutic use |
2 |
|
disability evaluation |
2 |
|
discrimination (psychology) - drug effects |
2 |
|
disease-modification |
2 |
|
dnm1l/drp1 |
2 |
|
dominance, cerebral - physiology |
2 |
|
down regulation |
2 |
|
drug- induced hepatotoxicity |
2 |
|
elderly |
2 |
|
electroencephalography |
2 |
|
emotion recognition |
2 |
|
emotions |
2 |
|
encephalitis - diagnosis - pathology |
2 |
|
environmental toxins |
2 |
|
epilepsy |
2 |
|
epilepsy - economics - rehabilitation |
2 |
|
epilepsy - etiology - physiopathology |
2 |
|
epilepsy, generalized |
2 |
|
epilepsy, reflex |
2 |
|
epilepsy, reflex - etiology |
2 |
|
executive dysfunction |
2 |
|
facial expression |
2 |
|
frontal lobe - physiopathology |
2 |
|
frontal-striatal circuit |
2 |
|
functional laterality |
2 |
|
gambling |
2 |
|
gene expression |
2 |
|
glucose - metabolism |
2 |
|
glucose/cerebrospinal fluid |
2 |
|
health care costs - statistics & numerical data - trends |
2 |
|
health services - standards - supply & distribution |
2 |
|
hemangioma, cavernous - diagnosis - physiopathology |
2 |
|
hospitalization - economics |
2 |
|
hospitals, public - economics |
2 |
|
hospitals, urban |
2 |
|
hypertension, malignant - diagnosis |
2 |
|
immunoglobulin fab fragments - administration & dosage - therapeutic use |
2 |
|
injections, intra-arterial |
2 |
|
intracranial arterial disease |
2 |
|
intracranial hemorrhages - diagnosis - pathology |
2 |
|
intracranial hypertension - microbiology |
2 |
|
intracranial thrombosis - diagnosis - epidemiology - etiology |
2 |
|
intraoperative complications - prevention & control |
2 |
|
ischemic cerebrovascular event |
2 |
|
knockin mice |
2 |
|
knockin mouse model |
2 |
|
length of stay |
2 |
|
leptomeningeal metastasis |
2 |
|
leucine-rich repeat kinase 2(lrrk2) |
2 |
|
levodopa - therapeutic use |
2 |
|
lrrk2 |
2 |
|
macroautophagy |
2 |
|
memory disorders - etiology - physiopathology |
2 |
|
meningeal neoplasms - diagnosis - secondary |
2 |
|
meningitis - diagnosis - etiology |
2 |
|
meningitis, cryptococcal - complications - diagnosis - drug therapy |
2 |
|
mental recall |
2 |
|
mesencephalon - physiopathology |
2 |
|
middle cerebral artery - pathology |
2 |
|
miller fisher syndrome - complications - therapy |
2 |
|
mitochondria dysfunction |
2 |
|
mitochondrial fission |
2 |
|
mitophagy |
2 |
|
monoamine oxidase-b inhibitors |
2 |
|
myasthenia gravis - etiology |
2 |
|
neoplasms, unknown primary |
2 |
|
nervous system -- diseases -- diagnosis. |
2 |
|
nervous system -- diseases -- treatment. |
2 |
|
nervous system -- diseases. |
2 |
|
nervous system diseases - diagnosis |
2 |
|
neurology. |
2 |
|
neuropsychological tests |
2 |
|
neuropsychological tests - statistics & numerical data |
2 |
|
oligomers |
2 |
|
outcome |
2 |
|
parkinson disease - complications - drug therapy - psychology |
2 |
|
parkinson disease - complications - physiopathology |
2 |
|
parkinson’s disease |
2 |
|
plaque, atherosclerotic - pathology |
2 |
|
platelet aggregation inhibitors - administration & dosage - therapeutic use |
2 |
|
pons |
2 |
|
postoperative complications - physiopathology |
2 |
|
prose memory |
2 |
|
protein aggregation |
2 |
|
protein degradation |
2 |
|
protein kinases |
2 |
|
psychomotor performance |
2 |
|
rab gtpase |
2 |
|
rasagiline |
2 |
|
recognition (psychology) |
2 |
|
recovery of function |
2 |
|
recreation |
2 |
|
red nucleus - physiopathology |
2 |
|
rehabilitation |
2 |
|
remission, spontaneous |
2 |
|
seizures - etiology - physiopathology |
2 |
|
selegiline |
2 |
|
signal transduction |
2 |
|
snp |
2 |
|
socioeconomic factors |
2 |
|
spinal puncture |
2 |
|
sqstm1/p62 |
2 |
|
status epilepticus - diagnosis - drug therapy - physiopathology |
2 |
|
stenting |
2 |
|
stents |
2 |
|
stroke - epidemiology - physiopathology - rehabilitation |
2 |
|
stroke - etiology - pathology |
2 |
|
stroke - prevention & control |
2 |
|
stroke classification |
2 |
|
stroke mechanism |
2 |
|
substance-related disorders - complications |
2 |
|
substantia nigra |
2 |
|
tag-1 |
2 |
|
therapeutic strategy |
2 |
|
thrombolytic |
2 |
|
tomography, emission-computed, single-photon |
2 |
|
tremor - etiology - physiopathology |
2 |
|
tuberculosis, meningeal - diagnosis - drug therapy - epidemiology |
2 |
|
ubiquitination |
2 |
|
urban population |
2 |
|
urinary incontinence - epidemiology - physiopathology - rehabilitation |
2 |
|
venous thrombosis - diagnosis - epidemiology - etiology |
2 |
|
verbal learning |
2 |
|
verbal memory |
2 |
|
visual perception - drug effects |
2 |
|
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine |
1 |
|
17β-estradiol |
1 |
|
alleles |
1 |
|
alzheimer disease - genetics |
1 |
|
antibody specificity |
1 |
|
antidepressive agents - pharmacology |
1 |
|
antiparkinson agents - adverse effects - therapeutic use |
1 |
|
antiparkinson agents - pharmacology - therapeutic use |
1 |
|
azathioprine |
1 |
|
azathioprine - adverse effects |
1 |
|
base sequence |
1 |
|
base sequence - genetics |
1 |
|
basilar artery - pathology |
1 |
|
basilar artery - pathology - physiopathology |
1 |
|
benzophenones - adverse effects - therapeutic use |
1 |
|
biogenic amines - metabolism |
1 |
|
blotting, northern |
1 |
|
brain - drug effects - metabolism |
1 |
|
brain - metabolism - pathology |
1 |
|
brain ischemia - radionuclide imaging |
1 |
|
brain stem - blood supply |
1 |
|
c-reactive protein - genetics - metabolism |
1 |
|
carcinogens - adverse effects |
1 |
|
catchment area (health) |
1 |
|
catechol o-methyltransferase - antagonists & inhibitors |
1 |
|
catechol o-methyltransferase - biosynthesis - genetics - immunology |
1 |
|
catechol o-methyltransferase - genetics |
1 |
|
catechol o-methyltransferase - metabolism |
1 |
|
catechol-o-methyltransferase |
1 |
|
catechol-o-methyltransferase (comt) |
1 |
|
ccaat-enhancer-binding proteins |
1 |
|
cerebellum - blood supply |
1 |
|
chromosome mapping |
1 |
|
chromosomes, human, pair 4 |
1 |
|
confusion - chemically induced |
1 |
|
corpus striatum - drug effects |
1 |
|
cos cells |
1 |
|
cox-2 |
1 |
|
cranial nerve diseases - diagnosis - etiology |
1 |
|
cyclooxygenase 2 |
1 |
|
cysteine dioxygenase |
1 |
|
cytochrome p-450 cyp2d6 - genetics |
1 |
|
cytochrome p-450 enzyme system - genetics - metabolism |
1 |
|
data interpretation, statistical |
1 |
|
debrisoquine 4-hydroxylase |
1 |
|
delirium, dementia, amnestic, cognitive disorders - radionuclide imaging |
1 |
|
dioxygenases |
1 |
|
dna - biosynthesis - genetics |
1 |
|
dna, recombinant |
1 |
|
dna-binding proteins - physiology |
1 |
|
dopamine agents - toxicity |
1 |
|
down-regulation |
1 |
|
down-regulation - drug effects |
1 |
|
drug administration schedule |
1 |
|
electromyography - radiation effects |
1 |
|
electrophoretic mobility shift assay |
1 |
|
england |
1 |
|
environmental agents |
1 |
|
enzyme activation - drug effects |
1 |
|
enzyme inhibitors - adverse effects - therapeutic use |
1 |
|
enzyme inhibitors - pharmacology - therapeutic use |
1 |
|
epilepsy - diagnosis - genetics - psychology |
1 |
|
epilepsy - epidemiology |
1 |
|
epilepsy - epidemiology - etiology |
1 |
|
estradiol - administration & dosage |
1 |
|
estrogen receptor |
1 |
|
estrogen response element |
1 |
|
estrogens - pharmacology |
1 |
|
estrogens - therapeutic use |
1 |
|
estrogens, conjugated (usp) - adverse effects - therapeutic use |
1 |
|
ethidium bromide |
1 |
|
ethidium- |
1 |
|
european continental ancestry group |
1 |
|
evoked potentials - physiology |
1 |
|
excitatory amino acid agonists - pharmacology |
1 |
|
facial nerve - pathology - physiopathology |
1 |
|
facial nerve diseases - diagnosis - physiopathology |
1 |
|
facial nerve root exit zone |
1 |
|
fluorescent-dyes |
1 |
|
formamide |
1 |
|
formamides- |
1 |
|
gene regulation |
1 |
|
genes, reporter |
1 |
|
genetic linkage |
1 |
|
genetic predisposition to disease |
1 |
|
genotype |
1 |
|
gonadal steroid hormones - administration & dosage |
1 |
|
great britain |
1 |
|
haplotypes - genetics |
1 |
|
hela cells |
1 |
|
hemifacial spasm |
1 |
|
hemifacial spasm - diagnosis - physiopathology |
1 |
|
hemifacial spasm - pathology - physiopathology |
1 |
|
herpes zoster |
1 |
|
herpes zoster - complications |
1 |
|
high-resolution mri/mra |
1 |
|
homeodomain proteins - genetics - metabolism |
1 |
|
hormone replacement therapy |
1 |
|
hospitals, teaching |
1 |
|
huntington disease - genetics |
1 |
|
image enhancement |
1 |
|
immunochemistry |
1 |
|
immunohistochemistry |
1 |
|
immunophenotyping |
1 |
|
isoenzymes - deficiency - genetics |
1 |
|
kainic acid |
1 |
|
kainic acid - pharmacology |
1 |
|
knockout mouse. mptp |
1 |
|
leiomyoma - enzymology |
1 |
|
lewy bodies - pathology |
1 |
|
lewy body |
1 |
|
lipopolysaccharides - pharmacology |
1 |
|
lymph nodes - pathology |
1 |
|
lymphoma |
1 |
|
lymphoma, b-cell - chemically induced - etiology |
1 |
|
lymphoma, non-hodgkin - chemically induced - diagnosis - etiology |
1 |
|
magnetic resonance angiography |
1 |
|
menstrual cycle |
1 |
|
mental disorders - diagnosis - epidemiology - etiology |
1 |
|
methyltransferases - metabolism |
1 |
|
mice |
1 |
|
mice, inbred c57bl |
1 |
|
mice, knockout |
1 |
|
molecular biology |
1 |
|
molecular sequence data |
1 |
|
monoamine oxidase - genetics |
1 |
|
motor fluctuations |
1 |
|
movement disorders - drug therapy - etiology |
1 |
|
nasopharyngeal neoplasms - radiotherapy |
1 |
|
neck muscles - radiation effects |
1 |
|
nerve compression syndromes - diagnosis - physiopathology |
1 |
|
nervous system diseases - diagnosis - genetics - therapy |
1 |
|
neurons - metabolism - pathology |
1 |
|
neuroprotective agents - therapeutic use |
1 |
|
neurovascular contact |
1 |
|
nicotinamide n-methyltransferase |
1 |
|
nitrophenols |
1 |
|
nuclear proteins - metabolism |
1 |
|
nuclear proteins - physiology |
1 |
|
oxygenases - metabolism |
1 |
|
paresis |
1 |
|
paresis - diagnosis - physiopathology - virology |
1 |
|
parkin |
1 |
|
parkinson disease - complications - drug therapy |
1 |
|
parkinson disease - drug therapy |
1 |
|
parkinson disease - drug therapy - physiopathology |
1 |
|
parkinson disease - enzymology - genetics |
1 |
|
parkinson disease - ethnology - genetics |
1 |
|
parkinson disease - etiology - genetics - metabolism |
1 |
|
parkinson disease - genetics |
1 |
|
parkinson disease - genetics - pathology - physiopathology |
1 |
|
parkinson disease, secondary - chemically induced - pathology |
1 |
|
parkinson-disease-physiopathology |
1 |
|
pd |
1 |
|
phosphorylation |
1 |
|
point mutation |
1 |
|
polymerase chain reaction |
1 |
|
polymorphism |
1 |
|
polymorphism, single-stranded conformational |
1 |
|
polymorphism,-single-stranded-conformational |
1 |
|
polymorphisms |
1 |
|
postmenopausal |
1 |
|
postmenopause - drug effects |
1 |
|
precipitin tests |
1 |
|
primary cell culture |
1 |
|
promoter regions, genetic - genetics |
1 |
|
promoter regions, genetic - genetics - physiology |
1 |
|
prostaglandin-endoperoxide synthases - deficiency - genetics |
1 |
|
proto-oncogene proteins c-fos - genetics |
1 |
|
radiation injuries - etiology |
1 |
|
rats, inbred f344 |
1 |
|
regional blood flow - physiology |
1 |
|
research design |
1 |
|
response elements - drug effects - genetics |
1 |
|
rna, messenger - metabolism |
1 |
|
s-adenosyl-l-methionine |
1 |
|
seizure |
1 |
|
seizures |
1 |
|
selective estrogen receptor modulators (serm) |
1 |
|
sequence analysis, dna |
1 |
|
serum amyloid p-component - genetics - metabolism |
1 |
|
sex characteristics |
1 |
|
shoulder - physiopathology |
1 |
|
single strand conformation polymorphism |
1 |
|
spinal nerve roots - pathology - physiopathology |
1 |
|
substantia nigra - drug effects |
1 |
|
substantia nigra - enzymology - pathology |
1 |
|
technetium tc 99m exametazime - diagnostic use |
1 |
|
temporal lobe - blood supply - radionuclide imaging |
1 |
|
time factors |
1 |
|
tomography, emission-computed |
1 |
|
torticollis - etiology |
1 |
|
transcription factors |
1 |
|
transcription, genetic - drug effects |
1 |
|
trinucleotide repeats |
1 |
|
tumor cells, cultured |
1 |
|
tyrosine 3-monooxygenase - metabolism |
1 |
|
tyrosine hydroxylase |
1 |
|
ubiquitin carboxy terminal hydroxylase l1 |
1 |
|
uterine neoplasms - enzymology |
1 |
|
uveitis - diagnosis - etiology |
1 |
|
uveomeningoencephalitic syndrome - complications - drug therapy |
1 |
|
vogt-kaganayi-harada (vkh) syndrome |
1 |
|
writing- |
1 |
|
xenobiotics - adverse effects - pharmacokinetics |
1 |
|
xenobiotics - metabolism |
1 |
|
α synuclein |
1 |
|
α-synuclein |
1 |
